VERTEX PHARMACEUTICALS INC

Vertex Pharmaceuticals reports $12B 2025 revenue, 33% EPS gain, and 2026 growth plans, plus orphan drug approval for myasthenia gravis—strong biopharma outlook.

Vertex Pharmaceuticals’ shares near record highs amid institutional selling; investors eye strong pipeline and upcoming clinical data.

Vertex Pharmaceuticals sees modest net‑sell institutional activity, yet buyers’ confidence in its biotech pipeline suggests long‑term growth potential amid market volatility.

Vertex Pharmaceuticals sees strong institutional buying and a $530 analyst upgrade, highlighting its pipeline strength and bullish near‑to‑mid‑term outlook.

Vertex Pharmaceuticals surges on analyst upgrades, institutional buying, and new FDA orphan‑drug status for its cystic‑fibrosis therapy – a bullish outlook toward $530 target.

Vertex Pharmaceuticals closed at $453.36 on Dec 30, 2025, falling beyond the NASDAQ‑100 yet staying backed by a strong pipeline and a $115 billion market cap—an attractive long‑term biotech play amid short‑term volatility.

Vertex Pharmaceuticals’ recent dip may signal a buying chance, with analysts boosting targets amid strong pipeline and high valuation expectations.

Vertex Pharmaceuticals: Analyst upgrade to $525, strong biotech pipeline, and market‑cap prospects for investors

Vertex Pharmaceuticals Inc. is a leading biotechnology company making significant strides in healthcare, with a strong financial foundation and a focus on delivering innovative treatments for critical medical conditions.

Vertex Pharmaceuticals’ stock price dropped sharply on May 7, 2025, following a mixed first-quarter earnings report that highlighted both revenue growth and international setbacks.